{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T19:00:57Z","timestamp":1774465257467,"version":"3.50.1"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2010,12,13]],"date-time":"2010-12-13T00:00:00Z","timestamp":1292198400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0014328","type":"journal-article","created":{"date-parts":[[2010,12,14]],"date-time":"2010-12-14T14:31:33Z","timestamp":1292337093000},"page":"e14328","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":192,"title":["Effects of Inhibition of Interleukin-6 Signalling on Insulin Sensitivity and Lipoprotein (A) Levels in Human Subjects with Rheumatoid Diseases"],"prefix":"10.1371","volume":"5","author":[{"given":"Olaf","family":"Schultz","sequence":"first","affiliation":[]},{"given":"Frank","family":"Oberhauser","sequence":"additional","affiliation":[]},{"given":"Jasemine","family":"Saech","sequence":"additional","affiliation":[]},{"given":"Andrea","family":"Rubbert-Roth","sequence":"additional","affiliation":[]},{"given":"Moritz","family":"Hahn","sequence":"additional","affiliation":[]},{"given":"Wilhelm","family":"Krone","sequence":"additional","affiliation":[]},{"given":"Matthias","family":"Laudes","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2010,12,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1210\/jc.2008-2291","article-title":"Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review.","volume":"94","author":"SH Golden","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/CIRCRESAHA.107.151621","article-title":"Adiposity and cardiovascular disorders: disturbance of the regulatory system consisting of humoral and neuronal signals.","volume":"101","author":"H Katagiri","year":"2007","journal-title":"Circ Res"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2174\/138955706776073501","article-title":"Cardiovascular disease in diabetes.","volume":"6","author":"S Yamagishi","year":"2006","journal-title":"Mini Rev Med Chem"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1210\/jc.2006-1055","article-title":"Relationship between adipocyte size and adipokine expression and secretion.","volume":"92","author":"T Skurk","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1172\/JCI26498","article-title":"MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity.","volume":"116","author":"H Kanda","year":"2006","journal-title":"J Clin Invest"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"26287","DOI":"10.1074\/jbc.274.37.26287","article-title":"Transmembrane tumor necrosis factor (TNF)-alpha inhibits adipocyte differentiation by selectively activating TNF receptor 1.","volume":"274","author":"H Xu","year":"1999","journal-title":"J Biol Chem"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0014-5793(00)01250-3","article-title":"Characterisation of receptor-specific TNFalpha functions in adipocyte cell lines lacking type 1 and 2 TNF receptors.","volume":"469","author":"JK Sethi","year":"2000","journal-title":"FEBS Lett"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.2165\/00003495-200565150-00014","article-title":"Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.","volume":"65","author":"MA Siddiqui","year":"2005","journal-title":"Drugs"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1517\/14712598.6.12.1349","article-title":"Adalimumab for rheumatoid arthritis.","volume":"6","author":"PV Voulgari","year":"2006","journal-title":"Expert Opin Biol Ther"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2165\/00063030-200923020-00005","article-title":"Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.","volume":"23","author":"V Oldfield","year":"2009","journal-title":"BioDrugs"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1586\/eci.10.69","article-title":"Certolizumab pegol: a new biologic targeting rheumatoid arthritis.","volume":"16","author":"AM Patel","year":"2010","journal-title":"Expert Rev Clin Immunol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-3083.2009.02296.x","article-title":"A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis.","volume":"70","author":"A Wiens","year":"2009","journal-title":"Scand J Immunol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3899\/jrheum.090074","article-title":"Anakinra for rheumatoid arthritis: a systematic review.","volume":"36","author":"M Mertens","year":"2009","journal-title":"J Rheumatol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/03009740601179605","article-title":"Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy.","volume":"36","author":"A Rosenvinge","year":"2007","journal-title":"Scand J Rheumatol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1159\/000088261","article-title":"Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes.","volume":"42","author":"H Dominguez","year":"2005","journal-title":"J Vasc Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa065213","article-title":"Interleukin-1-receptor antagonist in type 2 diabetes mellitus.","volume":"356","author":"CM Larsen","year":"2007","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1210\/jcem.86.3.7305","article-title":"Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women.","volume":"86","author":"JM Fernandez-Real","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.","volume":"112","author":"N Nishimoto","year":"2008","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1055\/s-2007-979893","article-title":"Plasma leptin levels and body fat distribution.","volume":"28","author":"M Takahashi","year":"1996","journal-title":"Horm Metab Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1007\/s00125-009-1508-3","article-title":"Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals.","volume":"52","author":"FM Finucane","year":"2009","journal-title":"Diabetologia"},{"key":"ref21","article-title":"Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis.","author":"SY Kawashiri","year":"2009","journal-title":"Rheumatol Int, epub"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"E745","DOI":"10.1152\/ajpendo.2001.280.5.E745","article-title":"Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance.","volume":"280","author":"PA Kern","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"812","DOI":"10.2337\/diabetes.52.3.812","article-title":"Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study.","volume":"52","author":"J Spranger","year":"2003","journal-title":"Diabetes"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.2337\/db06-0600","article-title":"IL6 gene promoter polymorphisms and type 2 diabetes: joint analysis of individual participants' data from 21 studies.","volume":"55","author":"C Huth","year":"2006","journal-title":"Diabetes"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.2337\/diabetes.54.suppl_2.S114","article-title":"Interleukin-6 and Diabetes.","volume":"54","author":"OP Kristiansen","year":"2005","journal-title":"Diabetes"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00125-004-1623-0","article-title":"Variations of the interleukin-6 promoter are associated with features of the metabolic syndrome in Caucasian Danes.","volume":"48","author":"YH Hamid","year":"2005","journal-title":"Diabetologia"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nm0102-75","article-title":"Interleukin-6-deficient mice develop mature-onset obesity.","volume":"8","author":"V Wallenius","year":"2002","journal-title":"Nat Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"E182","DOI":"10.1152\/ajpendo.00189.2003","article-title":"Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity.","volume":"287","author":"GB Di Gregorio","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1210\/en.2004-1468","article-title":"Interleukin-6 depletion selectively improves hepatic insulin action in obesity","volume":"146","author":"PJ Klover","year":"2005","journal-title":"Endocrinology"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1748-1716.2007.01779.x","article-title":"Role of interleukin-6 signalling in glucose and lipid metabolism.","volume":"192","author":"S Glund","year":"2008","journal-title":"Acta Physiol (Oxf)"},{"key":"ref31","first-page":"1","article-title":"IL-6 signal transduction and its physiological roles: the signal orchestration model.","volume":"149","author":"D Kamimura","year":"2003","journal-title":"Rev Physiol Biochem Pharmacol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.2337\/diabetes.53.9.2232","article-title":"Suppressor of cytokine signaling 3 expression and insulin resistance in skeletal muscle of obese and type 2 diabetic patients.","volume":"53","author":"J Rieusset","year":"2004","journal-title":"Diabetes"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/gerona\/61.6.575","article-title":"Interleukin-6 in aging and chronic disease: a magnificent pathway.","volume":"61","author":"M Maggio","year":"2006","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/j.1464-5491.2010.03043.x","article-title":"Associations between leptin and the leptin\/adiponectin ratio and incident Type 2 diabetes in middle-aged men and women: results from the MONICA\/KORA Augsburg study 1984-2002","volume":"27","author":"B Thorand","year":"2010","journal-title":"Diabet Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","article-title":"Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.","volume":"58","author":"MC Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","article-title":"Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.","volume":"54","author":"RN Maini","year":"2006","journal-title":"Arthritis Rheum"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1161\/01.CIR.102.10.1082","article-title":"Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies.","volume":"102","author":"J Danesh","year":"2000","journal-title":"Circulation"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen.","volume":"330","author":"JW McLean","year":"1987","journal-title":"Nature"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1021\/bi00015a028","article-title":"Antifibrinolytic effect of recombinant apolipoprotein(a) in vitro is primarily due to attenuation of tPA-mediated Glu-plasminogen activation.","volume":"34","author":"W Sangrar","year":"1995","journal-title":"Biochemistry"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1016\/S0735-1097(98)00469-0","article-title":"Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation.","volume":"32","author":"G Dangas","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1399-0004.1996.tb03281.x","article-title":"How often has Lp(a) evolved?","volume":"49","author":"RM Lawn","year":"1996","journal-title":"Clin Genet"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/00365510410005749","article-title":"Discrepancy of interleukin-6 levels between end-stage renal disease patients and patients with acute-phase response with increased lipoprotein(a) concentrations.","volume":"64","author":"KA Yun","year":"2004","journal-title":"Scand J Clin Lab Invest"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/art.20878","article-title":"Cardiovascular death in rheumatoid arthritis: a population-based study.","volume":"52","author":"H Maradit-Kremers","year":"2005","journal-title":"Arthritis Rheum"},{"key":"ref44","article-title":"Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab.","author":"A Ogata","year":"2010","journal-title":"Ann Rheum Dis Epub ahead of print"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0014328","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T02:17:40Z","timestamp":1559873860000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0014328"}},"subtitle":[],"editor":[{"given":"Kathrin","family":"Maedler","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2010,12,13]]},"references-count":44,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2010,12,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0014328","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,13]]}}}